Résumé
Methods: Using several isogenic cell models expressing HPV16 E6 and/or E7, the effect of viral oncoproteins on global DNA damage response was first investigated by in vitro/in vivo approaches. The binary interactome of each individual HPV oncoprotein with factors involved in the various host DNA damage/repair mechanisms was then precisely mapped by Gaussia princeps luciferase complementation assay (and validated by co-immunoprecipitation). The stability/half-life of protein targets for HPV E6 and/or E7 as well as their subcellular localizations were determined. At last, the host genome integrity following E6/E7 expression and the synergy between radiotherapy and compounds targeting DNA repair were analyzed.
Results: We first showed that the sole expression of one viral oncoprotein from HPV16 was able to significantly increase the sensitivity to irradiation of cells without affecting their basal viability parameters. In total, 10 novel targets (CHEK2, CLK2, CLK2/3, ERCC3, MNAT1, PER1, RMI1, RPA1, UVSSA and XRCC6) for E6 and 11 (ALKBH2, CHEK2, DNA2, DUT, ENDOV, ERCC3, PARP3, PMS1, PNKP, POLDIP2 and RBBP8) for E7 were identified. Importantly, not degraded following their interaction with E6 or E7, these proteins have been shown to be less linked to host DNA and to colocalize with HPV replication foci, denoting their crucial implication in viral life cycle. Finally, we found that E6/E7 oncoproteins globally jeopardize host genome integrity, increase the cellular sensitivity to DNA repair inhibitors and enhance their synergy with radiotherapy.
Conclusion: Taken together, our findings provide a molecular insight into the direct hijacking of host DNA damage/repair responses by HPV oncoproteins, demonstrate the significant impact of this phenomenon on both intrinsic cellular radiosensitivity and host DNA integrity and suggest novel connected therapeutic vulnerabilities.
| langue originale | Anglais |
|---|---|
| Pages (de - à) | 1130-1149 |
| Nombre de pages | 20 |
| journal | Theranostics |
| Volume | 13 |
| Numéro de publication | 3 |
| Les DOIs | |
| Etat de la publication | Publié - 2023 |
Financement
This work was supported in part by the FNRS (MIS F.4520.20, CDR J.0088.21), the University of Liege (Crédits Sectoriels de Recherche en Sciences de la Santé 2018-2021), the Télévie (PDR Televie 7.8507.19) and the Leon Fredericq Foundation. The authors thank the Biobank of the University of Liege as well as the GIGA-Immunohistochemistry, in vitro imaging, genomics and viral vector platforms (University of Liege) for their assistance. We are also grateful to Dr Stephanie Gofflot, Dr Emmanuel Di Valentin, Dr Wouter Coppieters, Dr Natacha Leroi, Dr Alain Jung (University of Strasbourg), Dr Marie-Julie Nokin, Raphael Thonon, Kamilia El Kandoussi, Tiffany Di Salvo, Hülya Kocadag, Nadine Cambisano, Manon Deckers, François Giroulle, Majid Cherkaoui, Bartimée Galvan and Fabienne Perin for their technical assistance. The graphical abstract was created with BioRender.com (agreement number: AJ24WBV3N3). TL, CP, CR and MA are Televie/FRIA fellows. DB and EH are postdoctoral scientific collaborators at FRS/FNRS. MH is a Research Associate at the Belgian Fund for Scientific Research (FNRS). This work was supported in part by the FNRS (MIS F.4520.20, CDR J.0088.21), the University of Liege (Crédits Sectoriels de Recherche en Sciences de la Santé 2018-2021), the Télévie (PDR Televie 7.8507.19) and the Leon Fredericq Foundation.
| Bailleurs de fonds | Numéro du bailleur de fonds |
|---|---|
| Belgian Fund for Scientific Research | 7.8507.19 |
| FRS | |
| Fonds de la Recherche Scientifique F.R.S.-FNRS | CDR J.0088.21 |
| Université de Liège | AJ24WBV3N3 |
| Fonds Léon Fredericq |